"Coherus divests Udenyca franchise to Intas for up to $558.4m" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been ...

2.9% of MiNK Therapeutics shares are held by institutional investors. Comparatively, 61.7% of Atyr PHARMA shares are held by institutional investors. 20.6% of MiNK Therapeutics shares are held by ...

Silo Pharma’s competitors have higher revenue and earnings than Silo Pharma. Silo Pharma is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more ...

Rayes as Head of Commercial, Global Efzofitimod Franchise. Ms. Rayes brings over 25 years of experience building and leading commercial organizations at biotechnology and pharmaceutical companies ...

SAN DIEGO - aTyr Pharma, Inc. (NASDAQ:ATYR), a clinical stage biotechnology company with a market capitalization of $310 million, announced the appointment of Dalia R. Rayes as the new Head of ...

Analysts believe the key question is whether India can be exempted from the pharma tariffs, given the better relationship between the countries and the critical nature of India’s generic drug ...

Hetero Group founder, B Parthasaradhi Reddy, warns of potential US reciprocal tariffs on Indian pharmaceuticals, which could disrupt India's pharma industry, leading to higher prices and reduced ...

Stock market today: Indian pharma stocks extended their losing streak to the third consecutive trading session on Thursday, March 27, as concerns grew that US President Donald Trump may announce ...

CAMBRIDGE, MA: Takeda SVP and head of global communications João Belo has departed the company for a new opportunity. Belo announced his departure in a LinkedIn post on Wednesday, teasing his “next ...

Zero. That revelation was part of a Senate Finance Committee investigation done by Democratic staff, released in March, that examined how U.S. pharmaceutical giants exploit a loophole created by ...